Find Clinical Trial

Home » Find Clinical Trials » A phase IIa efficacy and safety trial with intravenous S95011 in primary Sjögren’s Syndrome patients. An international, multicentre, randomised, double-blind, placebo-controlled study.

A phase IIa efficacy and safety trial with intravenous S95011 in primary Sjögren’s Syndrome patients. An international, multicentre, randomised, double-blind, placebo-controlled study.

← Back

Study Phase	Phase 2

Therapeutic Area	Immune-Inflammatory Diseases

Indication	Sjögren’s Syndrome

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	S095011

Active Substance Code	S095011

Protocol Code	CL2-95011-001

EudraCT Code	2020-001526-59

NCT Code	NCT04605978

Documents and links

Lay summary

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.